SpectraCure says China grants patent for Q-PRO prostate cancer treatment system design

• SpectraCure AB (publ) secured a patent in China covering core technology in its latest Q-PRO treatment system.
• The design enables a single optical fiber to deliver treatment light while also performing measurements to individualize dosing.
• The same patent has already been granted in Europe and Japan; reviews continue in other key markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpectraCure AB (publ) published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.